AJP - Heart AJP: Heart and Circulatory Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 278: H1008-H1015, 2000;
0363-6135/00 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawabata, K.-I.
Right arrow Articles by Dhalla, N. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawabata, K.-I.
Right arrow Articles by Dhalla, N. S.
Vol. 278, Issue 3, H1008-H1015, March 2000

RAPID COMMUNICATION
Mechanisms of ischemic preconditioning effects on Ca2+ paradox-induced changes in heart

Ken-Ichi Kawabata, Thomas Netticadan, Mitsuru Osada, Kohji Tamura, and Naranjan S. Dhalla

Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, and Department of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada R2H 2A6; and Second Department of Internal Medicine Yamanashi Medical University, Yamanashi 409-3898, Japan


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The effects of ischemic preconditioning (IP) on changes in cardiac performance and sarcoplasmic reticulum (SR) function due to Ca2+ paradox were investigated. Isolated perfused hearts were subjected to IP (three cycles of 3-min ischemia and 3-min reperfusion) followed by Ca2+-free perfusion and reperfusion (Ca2+ paradox). Perfusion of hearts with Ca2+-free medium for 5 min followed by reperfusion with Ca2+-containing medium for 30 min resulted in a dramatic decrease in the left ventricular (LV) developed pressure and a marked increase in LV end-diastolic pressure. Alterations in cardiac contractile activity due to Ca2+ paradox were associated with depressed SR Ca2+-uptake, Ca2+-pump ATPase, and Ca2+-release activities as well as decreased SR protein contents for Ca2+-pump and Ca2+ channels. All these changes due to Ca2+ paradox were significantly prevented in hearts subjected to IP. The protective effects of IP on Ca2+ paradox changes in cardiac contractile activity as well as SR Ca2+-pump and Ca2+-release activities were lost when the hearts were treated with 8-(p-sulfophenyl)-theophylline, an adenosine receptor antagonist; KN-93, a specific Ca2+/calmodulin-dependent protein kinase II (CaMK II) inhibitor; or chelerythrine chloride, a protein kinase C (PKC) inhibitor. These results indicate that IP rendered cardioprotection by preventing a depression in SR function in Ca2+ paradox hearts. Furthermore, these beneficial effects of IP may partly be mediated by adenosine receptors, PKC, and CaMK II.

ischemic preconditioning; calcium paradox; cardiac function; cardiac sarcoplasmic reticulum


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

BRIEF PERIODS OF MYOCARDIAL ischemia and reperfusion have been shown to render cardioprotection against a prolonged period of ischemia-reperfusion; this phenomenon has been termed as ischemic preconditioning (IP) (19). It has been previously reported that IP has beneficial effects with respect to myocardial infarct size, arrhythmias, and cellular injury due to ischemia-reperfusion (14, 19, 21, 26). Several endogenous agonists such as adenosine (14), norepinephrine (27), and bradykinin (7), as well as free radicals (5), have been implicated in mediating the beneficial effects of IP. Protein kinase C (PKC), a major signal transduction mechanism, has been shown to play an important role in protecting the ischemic-preconditioned heart (15). Other targets such as tyrosine kinase (6), ATP-sensitive K (KATP) channels (23), and phosphorylation by Ca2+/calmodulin-dependent protein kinase II (CaMK II) (20) have also been considered as mechanisms underlying the cardioprotective effects of IP. In a recent study, we have shown that IP exerted beneficial effects in hearts subjected to Ca2+ paradox (11), a phenomenon where a brief period of Ca2+ depletion followed by Ca2+ repletion results in marked myocardial cell damage and contractile dysfunction (31). Because both Ca2+ paradox and ischemia-reperfusion injury are known to be associated with the occurrence of intracellular Ca2+ overload (3, 24), it is possible that IP may elicit beneficial effects on the myocardium by preventing the development of intracellular Ca2+ overload. Whereas a great deal of work has been carried out to understand the mechanisms of the cardioprotective effects of IP with respect to alterations due to ischemia-reperfusion, the mechanisms underlying the IP-mediated cardioprotection of changes due to Ca2+ paradox are not known. Thus a study concerning the nature of IP effects on the Ca2+ paradox-induced alterations in the heart can be seen to provide further information in the area of cardioprotection.

Under physiological conditions, a small amount of Ca2+ entering through the L-type Ca2+ channels in the sarcolemmal (SL) membrane induces a release of Ca2+ from the sarcoplasmic reticulum (SR) stores and thus results in cardiac contraction (8). Cardiac relaxation occurs when the major part of the cytosolic Ca2+ is pumped back into the SR via the Ca2+-pump ATPase and the rest is extruded by the SL Na+/Ca2+ exchanger and the SL Ca2+-pump ATPase. Because of its remarkable ability to regulate the intracellular concentration of Ca2+, SR is known to play a central role in the contraction-relaxation cycle of the cardiac muscle (8). Earlier studies have demonstrated that IP may exert beneficial effects on the ischemia-reperfusion induced alterations in the SR Ca2+-uptake and Ca2+-release activities in the heart (2, 20, 32) and these may partly explain the cardioprotective effects of IP. Although an impairment in the SR function has been reported to occur in the Ca2+ paradox hearts (2), the effects of IP on Ca2+ paradox-induced changes in SR have not been investigated. The present study was therefore undertaken to examine the effects of IP on cardiac SR function by employing an isolated rat heart model of Ca2+ paradox. Because adenosine, PKC, and CaMK II (14, 15, 20) are considered to be important in mediating the effects of IP on ischemia-reperfusion-induced changes in the heart, we examined the role of these mediators in hearts subjected to Ca2+ paradox.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Heart perfusion and experimental protocol. Male Sprague-Dawley rats (300-350 g) were anesthetized by an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (10 mg/kg) mixture. The hearts were rapidly excised and perfused by the Langendorff procedure. The perfusion medium containing (in mmol/l) 120 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.25 CaCl2, and 11 glucose was gassed with 95% O2-5% CO2 and maintained at pH 7.4 at 37°C. The hearts were paced at 300 beats/min by an electrical stimulator (Phipp and Bird, Richmond, VA), and the coronary flow rate was maintained at 10 ml/min. For measuring the left ventricular pressure, the left atrium was removed and a latex balloon connected to a pressure transducer was inserted through the mitral valve into the left ventricle. The balloon was filled with the perfusion medium and adjusted to the left ventricular end-diastolic pressure (LVEDP) of 5-7 mmHg. Values for the left ventricular developed pressure (LVDP), rate of pressure development (+dP/dt), and rate of pressure decay (-dP/dt) were obtained through the program AcqKnowledge for Windows 3.0 (Biopac System, Goleta, CA). The balloon technique employed here allowed stable recording of the hemodynamic parameters over a period of more than 60 min. All hearts were stabilized for 30 min by perfusion with the oxygenated medium. The experimental protocols for inducing IP and Ca2+ paradox as well as for drug treatments are shown in Fig. 1. For the Ca2+ paradox group, the hearts were perfused for 18 min with oxygenated medium followed by 3 or 5 min of Ca2+-free perfusion and 30 min of repletion. The durations of Ca2+ depletion and repletion were adapted from our previous study (11). For the preconditioning group, the hearts were subjected to three cycles of 3-min global ischemia and 3-min reperfusion, followed by 3 or 5 min of Ca2+-free perfusion and 30 min of repletion. For the control group, the hearts were perfused for a comparable period with the oxygenated medium. To test whether the inhibitors of adenosine receptors, CaMK II, or PKC attenuate the protective effect of IP against Ca2+ paradox, we used 8-(p-sulfophenyl)-theophylline (8-SPT) (Research Biochemicals International, Natick, MA), KN-93 (Sigma Chemical, St. Louis, MO), or chelerythrine chloride (Sigma Chemical), respectively. The vehicle (perfusion medium) or each inhibitor was delivered by an infusion pump into the perfusion stream directly above the aortic cannula at 1 ml/min for 10 min before starting the preconditioning protocol as well as during the three cycles of intermittent reflow. The final concentrations of 8-SPT, KN-93, and chelerythrine were 10 µM, 1 µM, and 5 µM, respectively; these concentrations were selected on the basis of previous studies (11, 12, 16) showing inhibitory constant (Ki) value for 8-SPT for adenosine receptors (2.63 µM), KN-93 for CaMK II (0.37 µM), and chelerythrine for PKC (0.67 µM).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Experimental protocols. Protocol 1 indicates points at which changes in heart were examined before initiating Ca2+ depletion, at 5 min of Ca2+ depletion, at 10 min of Ca2+ repletion after 5 min of Ca2+ depletion, and at 30 min of Ca2+ repletion after 5 min of Ca2+ depletion. Protocol 2 indicates conditions under which changes in hearts subjected to 5-min Ca2+-free perfusion followed by 30 min of Ca2+ repletion were examined. Drug treatments were carried out 10 min before starting as well as during the three cycles of preconditioning. CP, Ca2+ paradox; IP, ischemic preconditioning; 8-SPT, adenosine antagonist 8-(p-sulfophenyl)-theophylline (10 µM); KN-93, Ca2+/calmodulin-dependent protein kinase (CaMK II) inhibitor (1 µM); CHT, PKC inhibitor chelerythrine chloride (5 µM). All hearts in this protocol were examined at 30 min of Ca2+ repletion.

Preparation of SR vesicles. The SR preparation was isolated by the method of Osada et al. (20) with slight modification. Briefly, the LV tissue was pulverized and homogenized twice for 20 s each at a one-half maximal setting using a Polytron homogenizer (Brinkmann, Westbury, NY). The homogenization buffer contained (in mmol/l) 10 NaHCO3, 5 NaN3, 15 Tris · HCl, pH 6.8, and protease inhibitors (in µmol/l): 1 leupeptin, 1 pepstatin, and 100 phenylmethylsulfonyl fluoride. The homogenate was then centrifuged for 20 min at 9,500 rpm (Beckman, JA 20.0), and the supernatant was further centrifuged for 45 min at 19,000 rpm (Beckman, JA 20.0). The pellet obtained was suspended in a buffer containing 0.6 M KCl and 20 mM Tris · HCl, pH 6.8, and recentrifuged at the same speed and duration as indicated in the previous step. The resulting pellet obtained was suspended in a mixture of 250 mM sucrose and 10 mM histidine, pH 7.0. All steps were performed at 0-4°C, and the resulting SR preparation was used for various assays. The purity of the SR preparations was determined by measuring the activities of marker enzymes such as ouabain-sensitive Na+-K+-ATPase, cytochrome-c oxidase, glucose-6-phosphatase, and rotenone-insensitive NADPH cytochrome-c reductase according to methods described earlier (1). The SR preparations from all groups were found to contain minimal (3-5%) but equal cross contamination by other subcellular organelles.

Measurement of Ca2+-uptake activity. Ca2+-uptake activity of SR membranes was determined by the procedure described earlier (20) with slight modifications. The standard reaction mixture (total volume 250 µl) contained (in mmol/l) 50 Tris-maleate (pH 6.8), 5 NaN3, 5 ATP, 5 MgCl2, 120 KCl, 5 K-oxalate, 0.1 EGTA, 0.1 45CaCl2 (12,000 counts · min-1 · nmol-1), and 0.025 ruthenium red. The initial free Ca2+ in this medium determined by the program of Fabiato (9) was 8.2 µmol/l. Ruthenium red was added to inhibit Ca2+-release channel activity under these conditions. The reaction was initiated by the addition of SR membranes to the Ca2+-uptake reaction mixture and terminated after 1 min by filtering a 200-µl aliquot of the reaction mixture. The filters were washed, dried, and counted in a beta liquid scintillation counter.

Determination of Ca2+-stimulated ATPase activities. The status of the Ca2+ pump in the SR membranes was determined by measuring the Ca2+-stimulated ATPase activities according to the method used previously (10). Total (Mg2+ and Ca2+) and basal (Mg2+) ATPase activities were determined in the presence or absence of Ca2+ in a reaction medium containing (in mmol/l) 100 KCl, 20 Tris · HCl, 5 MgCl2, and 5 NaN3, respectively. The reaction was started by the addition of 5 mM Tris · ATP in the presence of 0.05 mg/ml of SR protein and was terminated with 12% cold TCA. Inorganic phosphate liberated during the reaction was estimated in the protein-free filtrate by a spectrophotometric method (10). The Ca2+-stimulated, Mg2+-dependent ATPase (Ca2+-pump ATPase) activity was calculated as the difference between the total and basal ATPase activities.

Measurement of ryanodine-sensitive, Ca2+-induced Ca2+ release. The Ca2+-release activity of SR vesicles was measured by a procedure described previously (20). In brief, the SR fraction (62 µg protein) was suspended in a total volume of 625 µl of loading buffer containing (in mmol/l) 100 KCl, 5 MgCl2, 5 K-oxalate, 5 NaN3, and 20 Tris · HCl (pH 6.8). After incubation with 10 µM 45CaCl2 (20 mCi/l) and 5 mM ATP for 45 min at room temperature, Ca2+-induced Ca2+ release was carried out by adding 1 mM EGTA plus 1 mM CaCl2 to the reaction mixture. The reaction was terminated at 15 s by filtering a 100-µl aliquot of the reaction mixture. The filters were washed, dried, and counted in a beta scintillation counter. The Ca2+-induced Ca2+ release was completely prevented (90-97%) by the treatment of SR with 20 µM ryanodine.

Western blot analysis. The protein contents of Ca2+-release channel [ryanodine receptor (RyR)], Ca2+ pump [sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2)], and phospholamban (PLB) in the SR membrane were determined by Western immunoblotting techniques. For immunoassay of RyR, SERCA2a, and PLB, SR (20 µg protein/lane) samples were subjected to SDS-PAGE in 6%, 10%, and 15% gels, respectively. The quantity of protein loaded was within the linear range (14). The protein bands from these gels were then transferred electrophoretically to nitrocellulose membrane (for RyR) or polyvinylidene difluoride membrane (for SERCA2a and PLB). The membranes were used for incubation with anti-RyR receptor (1:1400), anti-SERCA2 (1:1400), or anti-PLB (1:3500) antibodies. A peroxidase-linked, anti-mouse IgG was used for SERCA2a or PLB as the secondary antibody (1:5000), whereas anti-mouse IgG was used for Ca2+-release channel as the secondary antibody (1:2500) and then incubated with streptavidin-conjugated horseradish peroxidase solution (1:5000). Protein bands reactive with antibodies were visualized using the ECL detection system from Amersham (Buckinghamshire, UK). The intensity of each band was scanned by Imaging Densitometer with the aid of Molecular Analyst Software version 1.3 (Bio-Rad, Hercules, CA). After the detection of SR proteins by Western blot analysis, the membranes were stained with Coomassie Blue, and each lane was scanned to normalize the well-to-well variability in protein loading. The total intensity of the bands in each lane was calculated, but no significant changes in total intensity were observed among different lanes.

Statistical analysis. Data are expressed as means ± SE. The statistical difference among different groups was determined by factorial ANOVA (Statview 4.02, Abacus Concepts). All groups were analyzed with post hoc testing by the Scheffé's procedure. P < 0.05 was considered to be significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Left ventricular function and Ca2+ uptake. Changes in the left ventricular function and SR Ca2+ uptake due to Ca2+ paradox with or without IP are shown in Fig. 2. During predepletion phase, IP did not affect the LVDP, LVEDP, and SR Ca2+ uptake; there was no change in LVEDP in hearts that did not undergo IP. Ca2+-free perfusion for 5 min (depletion phase) produced a marked depression of LVDP and SR Ca2+-uptake activity in hearts with or without IP; however, the extent of changes in both conditions was similar. A marked increase in LVEDP and a depression in SR Ca2+-uptake activity were seen on perfusing the Ca2+-depleted hearts with normal medium for 10 or 30 min without any recovery in LVDP. At the 10-min repletion phase, IP significantly improved the recovery of LVDP and decreased the LVEDP of the Ca2+ paradox hearts; however, there was no significant difference in SR Ca2+-uptake activities between groups with or without IP. At the 30-min repletion phase, IP significantly improved LVDP as well as SR Ca2+ uptake and markedly decreased the LVEDP of the Ca2+ paradox hearts (Fig. 2).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Left ventricular (LV) function and sarcoplasmic reticulum (SR) Ca2+-uptake activities in CP hearts with or without IP. Top: percentage recovery of LV developed pressure (LVDP). Values for LVDP are expressed as % of basal values (82.6 ± 3.42 mmHg). Middle: LV end-diastolic pressure (LVEDP). Bottom: SR Ca2+-uptake activities. Hearts were examined before Ca2+ depletion, at 5 min after Ca2+ depletion, at 10 min after Ca2+ repletion after 5 min of Ca2+ depletion, and at 30 min after Ca2+ repletion after 5 min of Ca2+ depletion. Each value is a mean ± SE of 6 hearts in each group. *P < 0.05 vs. CP without IP.

SR protein content in IP and Ca2+ paradox. The SR content of RyR, SERCA2a, and PLB in control and Ca2+ paradox hearts with and without IP were determined by using the Western blot analysis and values are expressed as percentage of control (Fig. 3, B and C). The density of each band from the control heart was considered to be 100%, and the other groups CP, IP, and IP plus CP were compared with this control value. RyR, SERCA2a, and PLB protein levels did not change due to IP when compared with control value. On the other hand, RyR, SERCA2a, and PLB protein levels in the Ca2+ paradox hearts were decreased by 94.6%, 96.8%, and 44.7% of the control value, respectively. IP significantly prevented the depression in protein content of RyR and SERCA2a due to Ca2+ paradox. Although PLB content in the Ca2+ paradox hearts was 17.3% higher on treatment with IP, this change was not significant.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of ischemic preconditioning and CP on SR protein content in rat heart. Western blot autoradiograms and analysis of ryanodine receptor (A), sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2a) (B), and phospholamban (PLB) (C) of SR protein content in control (C), IP, CP, and IP + CP. Each value is a mean ± SE of 4 separate experiments. *P < 0.05 vs. C and dagger  vs. CP.

Modification of changes in cardiac function. The effects of IP on cardiac performance in Ca2+ paradox induced by 5-min Ca2+ depletion and 30-min Ca2+ repletion with or without some inhibitor treatments are shown in Table 1. Hearts subjected to Ca2+ paradox under control conditions showed significant depressions in LVDP, +dP/dt, and -dP/dt and a marked increase in LVEDP in comparison with the control values. 8-SPT, KN-93, or chelerythrine treatment did not affect the LV function of the Ca2+ paradox hearts significantly. On the other hand, IP improved the recovery of LVDP, +dP/dt, as well as -dP/dt significantly and markedly reduced the increase in LVEDP in the Ca2+ paradox hearts. Treatments with 8-SPT, KN-93, or chelerythrine abolished these beneficial effects of IP.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Left ventricular performance in the control and Ca2+ paradox hearts with or without ischemic preconditioning

Modification of changes in SR Ca2+ uptake and Ca2+ pump ATPase activities. Oxalate-supported SR Ca2+-uptake activities were determined in SR preparations in the control and Ca2+ paradox hearts (5-min Ca2+ depletion and 30-min Ca2+ repletion) with or without some inhibitor treatments and the results are shown in Fig. 4. The Ca2+-uptake activity was significantly reduced in Ca2+ paradox hearts in comparison with control hearts. IP prevented the decrease in SR Ca2+ uptake due to Ca2+ paradox significantly; this improvement was attenuated with 8-SPT, KN-93, or chelerythrine treatment. To show whether the observed changes in SR Ca2+ uptake were due to alterations in the SR Ca2+-pump, Ca2+-stimulated ATPase activities were determined. The results in Fig. 5 reveal that the SR Ca2+-pump ATPase activity in the Ca2+ paradox hearts was significantly reduced in comparison to control hearts. IP improved Ca2+-pump ATPase activity of the Ca2+ paradox hearts; this beneficial effect of IP was lost on treatment with 8-SPT, KN-93, or chelerythrine.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 4.   SR Ca2+-uptake activities in control and CP hearts with and without IP. SR Ca2+ uptake was measured at 30 min of Ca2+ repletion as described in Fig. 1. Each value is a mean ± SE of 5 different preparations in each group. *P < 0.05 vs. control, #P < 0.05 vs. CP + IP.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   SR Ca2+-stimulated ATPase activities in control and CP hearts with and without IP. SR Ca2+-ATPase activities were determined at 30 min of Ca2+ repletion as described in Fig. 1. Each value is a mean ± SE of 5 different preparations in each group. *P < 0.05 vs. control, #P < 0.05 vs. CP with IP.

Modification of changes in SR Ca2+-release activity. The Ca2+-induced Ca2+-release activity was determined in SR preparations from the control and Ca2+ paradox hearts (5-min Ca2+ depletion and 30-min Ca2+ repletion) with or without some inhibitor treatments and results are shown in Fig. 6. Hearts subjected to Ca2+ paradox exhibited a significant depression of the SR Ca2+-release activity in comparison with control; IP attenuated the reduction in SR Ca2+ release in Ca2+ paradox hearts. This improvement due to IP was lost when the hearts were treated with 8-SPT, KN-93, or chelerythrine.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 6.   SR Ca2+-release activities in control and CP hearts with and without IP. SR Ca2+-release activities were determined at 30 min of Ca2+ repletion as described in Fig. 1. Each value is a mean ± SE of 5 different preparations in each group. *P < 0.05 vs. control, #P < 0.05 vs. CP with IP.

Modification of changes due to mild Ca2+ paradox. Because perfusion for 5 min with Ca2+-free medium and reperfusion for 30 min with Ca2+-containing medium produced severe changes in the heart, some experiments were carried out to examine the effects of IP on changes in SR function due to a mild Ca2+ paradox injury induced by 3-min Ca2+ depletion and 30-min Ca2+ repletion (Table 2). The mild Ca2+ paradox was associated with a significant decrease in LVDP, a marked increase in LVEDP, as well as significant decreases in SR Ca2+-uptake, Ca2+-pump ATPase, and Ca2+-release activities in comparison to the control values. IP prevented the reduction in LVDP and the increase in LVEDP significantly in addition to preventing changes in SR Ca2+ uptake, Ca2+-pump ATPase, and Ca2+-release activities in the Ca2+ paradox hearts.

                              
View this table:
[in this window]
[in a new window]
 
Table 2.   Left ventricular performance and SR function in control and mild Ca2+ paradox with or without ischemic preconditioning


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In this study we have provided evidence for a significant protection by IP against SR dysfunction due to Ca2+ paradox induced by perfusing the heart for 5 min with a Ca2+-free medium followed by reperfusion with Ca2+-containing medium for 30 min. The beneficial effects of IP were also evident under a mild Ca2+ paradox condition where the hearts were subjected to 3-min Ca2+-free perfusion and 30-min reperfusion with a normal medium. Although several mechanisms have been put forward to explain the beneficial effects of IP against the ischemia-reperfusion-induced changes in the heart, attenuation of cytosolic Ca2+ overload appears to be a major factor (24). In fact, the intracellular Ca2+ overload is considered to be the hallmark of Ca2+ paradox injury (3) and is believed to be due to an alteration in the ability of the myocardium to regulate the level of intracellular Ca2+ (17). Such an alteration in the Ca2+ paradox heart has been shown to be in part due to a defect in the SR function (2), which is considered to be intimately involved in intracellular Ca2+ homeostasis and cardiac excitation-contraction coupling (8). Changes in the SR Ca2+ uptake and Ca2+-release activities have also been shown to occur during other pathological conditions, resulting in the occurrence of intracellular Ca2+ overload and subsequent cardiac dysfunction (1, 10, 22). Thus the observed alterations in SR Ca2+-pump and Ca2+-release activities as well as SR Ca2+-pump and Ca2+-release channel proteins in hearts subjected to Ca2+ paradox are consistent with impaired cardiac function in this experimental condition. In addition, we have demonstrated that the recovery of cardiac functions in Ca2+ paradox hearts by IP was associated with the ability of IP to partially prevent changes in SR Ca2+-uptake, Ca2+-pump ATPase, and Ca2+-release activities as well as SR Ca2+-pump and Ca2+-release channel proteins. These observations allow us to speculate that IP rendered cardioprotection by reducing the intracellular Ca2+ overload via an improved Ca2+-handling ability of the SR in Ca2+ paradox hearts.

Since Murry et al. (19) observed the phenomenon of IP, many factors have been proposed to explain the beneficial effects of IP (29). In particular, the formation of adenosine and subsequent activation of adenosine receptors in the heart have been suggested to be an important mediator of IP (14). However, the role of adenosine in mediating IP in rat hearts has been questioned because pretreatment with an adenosine receptor blocker failed to prevent the ischemia-reperfusion damage (13). On the other hand, Ashraf et al. (4) reported that adenosine may be involved in Ca2+ preconditioning for conferring significant protection against the Ca2+ paradox injury in the rat heart (4). Moreover, adenosine acting via A1 receptors has also been shown to render significant cardioprotection against rat hearts subjected to Ca2+ paradox (25). The results in the present study have shown that the beneficial effects of IP on SR function were abolished by pretreatment of the heart with 8-SPT, an adenosine receptor antagonist. Thus it is likely that the formation of adenosine may be one of the mechanisms by which IP protects the heart against Ca2+ paradox injury. Although on the basis of the effects of 8-SPT, which is known to act on the adenosine A1 receptors (14, 25), it appears that A1 receptors may be involved in the IP-induced cardioprotection against Ca2+ paradox, the involvement of other types of adenosine receptors cannot be ruled out at this time.

In view of the fact that the activation of PKC plays a central role in IP (15, 29), Miyawaki et al. (16) demonstrated that a transient increase in intracellular Ca2+ concentration during IP represents the trigger for the activation of PKC and subsequent cardioprotection against the ischemic-reperfusion injury. Moreover, Movsesian et al. (18) reported that PKC may regulate Ca2+ uptake by cardiac SR via phosphorylation of PLB. In this study, we show that the treatment of hearts with a PKC inhibitor, chelerythrine, attenuated the beneficial effects of IP on SR function in Ca2+ paradox hearts. Our results regarding IP are consistent with a recent study demonstrating a role for PKC in the protection against Ca2+-paradox injury by Ca2+ preconditioning in the rat heart (28). Because Osada et al. (20) reported that IP prevented alterations in the SR CaMK II-mediated phosphorylation of SR Ca2+-cycling proteins as well as SR and cardiac functions in the ischemia-reperfused hearts, the SR CaMK II can also be seen to represent an important mechanism underlying the beneficial effects of IP against the ischemic-reperfusion injury in the isolated rat heart. In the present study, we also show that the treatment of hearts with a CaMK II inhibitor, KN-93, attenuated the beneficial effects of IP on the SR function in the Ca2+ paradox hearts. Thus it appears that the activation of both PKC and CaMK II in addition to adenosine receptors may represent the mechanisms by which IP protects the hearts against the Ca2+ paradox injury. Extensive research is required to establish whether adenosine receptors, PKC, and CaMK II represent three parallel pathways or act sequentially leading to protection of the Ca2+ paradox heart by IP.

Although the observed reduction in SR Ca2+ uptake and Ca2+-release activities due to Ca2+ paradox and the protection of SR function due to IP can be explained on the basis of corresponding changes in SERCA2a and RyR protein contents of the SR membrane, the depressed levels of PLB protein in the Ca2+ paradox heart can be seen to relieve the inhibitory effect of PLB on the SR Ca2+ pump and thus increase the Ca2+-uptake activity. However, this effect due to the reduction of PLB content may not be sufficient to compensate for the depression in the SR Ca2+-uptake activity due to the loss of SERCA2a, because the reduction in the SERCA2a level was considerably greater than that in the PLB content in the Ca2+ paradox heart. The loss of SR proteins in hearts subjected to Ca2+ paradox may be due to the activation of proteases because intracellular Ca2+ overload under pathological conditions such as ischemia-reperfusion has been reported to result in SR protein degradation due to protease activation (30). It should be pointed out that the loss of proteins may not be a generalized phenomenon in the paradoxic hearts because the loss of PLB in the SR membrane due to Ca2+ paradox with or without IP was considerably smaller than that of RyR and SERCA2a proteins. Furthermore, other proteins such as inhibitory guanine binding proteins and beta 2-adrenergic receptor proteins were unaltered under similar conditions of Ca2+ paradox (unpublished observations). In view of the role of KATP channels in the protective effect of IP against the ischemia-reperfusion injury (23), it is possible that KATP channels may also mediate the beneficial effects of IP against Ca2+ paradox with respect to changes in cardiac contractile activity. However, such a mechanism cannot be invoked to explain the beneficial effects of IP against the Ca2+ paradox-induced or ischemic-reperfusion-induced (20) changes in SR function because the relationship between KATP channels and the SR Ca2+ transport system is not understood at the present time.


    ACKNOWLEDGEMENTS

This work was supported by a grant from the Medical Council of Canada (MRC Group in Experimental Cardiology). N. S. Dhalla holds the MRC/Pharmaceutical Research and Development Chair in Cardiovascular Research supported by Merck Frosst, Canada.


    FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Address for reprint requests and other correspondence: N. S. Dhalla, Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, 351 Taché Ave., Winnipeg, MB, Canada R2H 2A6 (E-mail: cvso{at}sbrc.umanitoba.ca).

Received 29 July 1999; accepted in final form 2 December 1999.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Afzal, N., and N. S. Dhalla. Differential changes in left and right ventricular SR calcium transport in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol. 262: H868-H874, 1992[Abstract/Free Full Text].

2.   Alto, L. E., and N. S. Dhalla. Role of changes in microsomal calcium uptake in the effects of reperfusion of Ca2+-deprived rat hearts. Circ. Res. 48: 17-24, 1981[Abstract/Free Full Text].

3.   Alto, L. E., and N. S. Dhalla. Myocardial cation contents during induction of the calcium paradox. Am. J. Physiol. Heart Circ. Physiol. 237: H713-H719, 1979.

4.   Ashraf, M., J. Suleiman, and M. Ahmad. Ca2+ preconditioning elicits a unique protection against the Ca2+ paradox injury in rat heart. Role of adenosine. Circ. Res. 74: 360-367, 1994[Abstract/Free Full Text].

5.   Baines, C. P., M. Goto, and J. M. Downey. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J. Mol. Cell Cardiol. 29: 207-216, 1997[Web of Science][Medline].

6.   Baines, C. P., L. Wang, M. V. Cohen, and J. M. Downey. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J. Mol. Cell Cardiol. 30: 383-392, 1998[Web of Science][Medline].

7.   Brew, E. C., M. B. Mitchell, T. F. Rehring, F. Gamboni-Robertson, R. C. Mclntyre, A. H. Harken, and A. Banerjee. Role of bradykinin in cardiac functional protection after global ischemia-reperfusion in rat heart. Am. J. Physiol. Heart Circ. Physiol. 269: H1370-H1378, 1995[Abstract/Free Full Text].

8.   Dhalla, N. S., X. Wang, and R. E. Beamish. Intracellular calcium handling in normal and failing hearts. Exptl. Clin. Cardiol. 1: 7-20, 1996.

9.   Fabiato, A. Computer program for calculating total from specific free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. Methods Enzymol. 157: 378-417, 1988[Web of Science][Medline].

10.   Ganguly, P. K., G. N. Pierce, K. S. Dhalla, and N. S. Dhalla. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am. J. Physiol. Endocrinol. Metab. 244: E528-E535, 1983[Abstract/Free Full Text].

11.   Kawabata, K., M. Osada, T. Netticadan, and N. S. Dhalla. Beneficial effect of ischemic preconditioning on Ca2+ paradox in the rat heart. Life Sci. 63: 685-692, 1998[Web of Science][Medline].

12.   Li, L., H. Satoh, K. S. Giusburg, and D. M. Bers. The effect of Ca2+-calmodulin-dependent protein kinase II on cardiac excitation-contraction coupling in ferret ventricular myocytes. J. Physiol. (Lond.) 501: 17-32, 1997[Abstract/Free Full Text].

13.   Li, Y., and R. A. Kloner. The cardioprotective effects of ischemic "preconditioning" are not mediated by adenosine receptors in rat hearts. Circulation 87: 1642-1648, 1993[Abstract/Free Full Text].

14.   Liu, G. S., J. Thoronton, D. M. Van Winkle, A. W. H. Stanley, R. A. Olsson, and J. M. Downey. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84: 350-356, 1991[Abstract/Free Full Text].

15.   Mitchell, M. B., X. Meng, L. Ao, J. M. Brown, A. H. Harken, and A. Banerjee. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ. Res. 76: 73-81, 1995[Abstract/Free Full Text].

16.   Miyawaki, H., and M. Ashraf. Ca2+ as a mediator of ischemic preconditioning. Circ. Res. 80: 790-799, 1997[Abstract/Free Full Text].

17.   Morgan, J. P. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N. Engl. J. Med. 325: 625-632, 1991[Web of Science][Medline].

18.   Movsesian, M. A., M. Nishikawa, and R. S. Adelstein. Phosphorylation of phospholamban by calcium-activated, phospholipid-dependent protein kinase. J. Biol. Chem. 259: 8029-8032, 1984[Abstract/Free Full Text].

19.   Murry, C. E., R. B. Jennings, and K. A. Reimer. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986[Abstract/Free Full Text].

20.   Osada, M., T. Netticadan, K. Tamura, and N. S. Dhalla. Modification of ischemic-reperfusion-induced changes in cardiac sarcoplasmic reticulum by preconditioning. Am. J. Physiol. Heart Circ. Physiol. 274: H2025-H2034, 1998[Abstract/Free Full Text].

21.   Osada, M., T. Sato, S. Komori, and K. Tamura. Protective effect of preconditioning on reperfusion induced ventricular arrhythmias of isolated rat hearts. Cardiovasc. Res. 25: 441-444, 1991[Abstract/Free Full Text].

22.   Phillips, R. M., P. Narayan, A. M. Gómez, K. Dilly, L. R. Jones, W. J. Lederer, and R. A. Altschuld. Sarcoplasmic reticulum in heart failure: central player or bystander? Cardiovasc. Res. 37: 346-351, 1998[Free Full Text].

23.   Schultz, J. E. J., Y. Z. Qian, G. J. Gross, and R. C. Kukreja. The ischemic-selective KATP channel antagonist, 5-Hydroxydecanoate, blocks ischemic preconditioning in the rat heart. J. Mol. Cell Cardiol. 29: 1055-1060, 1997[Web of Science][Medline].

24.   Steenbergen, C., M. E. Perlman, R. E. London, and E. Murphy. Mechanism of preconditioning. Ionic alterations. Circ. Res. 72: 112-125, 1993[Abstract/Free Full Text].

25.   Suleiman, J., and M. Ashraf. Adenosine attenuates calcium praradox injury: role of adenosine A1 receptor. Am. J. Physiol. Cell Physiol. 268: C838-C845, 1995[Abstract/Free Full Text].

26.   Tani, M., Y. Asakura, H. Hasegawa, K. Shinmura, Y. Ebihara, and Y. Nakomura. Effect of preconditioning on ryanodine-sensitive Ca2+ release from sarcoplasmic reticulum of rat heart. Am. J. Physiol. Heart Circ. Physiol. 271: H876-H881, 1996[Abstract/Free Full Text].

27.   Tsuchida, A., Y. Liu, G. S. Liu, M. V. Cohen, and J. M. Downey. alpha 1-Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ. Res. 75: 576-785, 1994[Abstract/Free Full Text].

28.   Wang, Y., and M. Ashraf. Activation of alpha 1-adrenergic receptor during Ca2+ preconditioning elicits strong protection against Ca2+ overload injury via protein kinase C signaling pathway. J. Mol. Cell. Cardiol. 30: 2423-2435, 1998[Web of Science][Medline].

29.   Yellon, D. M., G. F. Baxter, D. Garcia-Dorado, G. Heusch, and M. S. Sumeray. Ischemic preconditioning: present position and future directions. Cardiovasc. Res. 37: 21-33, 1998[Abstract/Free Full Text].

30.   Yoshida, Y., T. Shiga, and S. Imai. Degradation of sarcoplasmic reticulum calcium-pumping ATPase in ischemic-reperfused myocardium: role of calcium-activated neutral protease. Basic Res Cardiol. 85: 495-507, 1990[Web of Science][Medline].

31.   Zimmerman, A. N. E., and W. C. Hulsmann. Paradoxical influence of calcium ions on the permeability of the cell membranes of the isolated rat heart. Nature 211: 646-647, 1966[Medline].

32.   Zucchi, R., S. Ronca-Testoni, G. Yu, P. Galbani, G. Ronca, and M. Mariani. Postischemic changes in cardiac sarcoplasmic reticulum Ca2+ channels. A possible mechanism of ischemic preconditioning. Circ. Res. 76: 1049-1056, 1995[Abstract/Free Full Text].


Am J Physiol Heart Circ Physiol 278(3):H1008-H1015
0363-6135/00 $5.00 Copyright © 2000 the American Physiological Society



This article has been cited by other articles:


Home page
Exp PhysiolHome page
W. Hleihel, A. Lafoux, N. Ouaini, A. Divet, and C. Huchet-Cadiou
Adenosine affects the release of Ca2+ from the sarcoplasmic reticulum via A2A receptors in ferret skinned cardiac fibres
Exp Physiol, July 1, 2006; 91(4): 681 - 691.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Xie, Y. Zhu, W.-Z. Zhu, L. Chen, Z.-N. Zhou, W.-J. Yuan, and H.-T. Yang
Role of dual-site phospholamban phosphorylation in intermittent hypoxia-induced cardioprotection against ischemia-reperfusion injury
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2594 - H2602.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Q. Chen, A. K. S. Camara, J. An, M. L. Riess, E. Novalija, and D. F. Stowe
Cardiac preconditioning with 4-h, 17{degrees}C ischemia reduces [Ca2+]i load and damage in part via KATP channel opening
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H1961 - H1969.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. M. Temsah, K. Kawabata, D. Chapman, and N. S. Dhalla
Preconditioning prevents alterations in cardiac SR gene expression due to ischemia-reperfusion
Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1461 - H1466.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. An, S. G. Varadarajan, E. Novalija, and D. F. Stowe
Ischemic and anesthetic preconditioning reduces cytosolic [Ca2+] and improves Ca2+ responses in intact hearts
Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1508 - H1523.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Mubagwa and W. Flameng
Adenosine, adenosine receptors and myocardial protection: An updated overview
Cardiovasc Res, October 1, 2001; 52(1): 25 - 39.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
T. L. Clanton, V. P. Wright, P. J. Reiser, P. F. Klawitter, and N. R. Prabhakar
Physiological and Genomic Consequences of Intermittent Hypoxia: Selected Contribution: Improved anoxic tolerance in rat diaphragm following intermittent hypoxia
J Appl Physiol, June 1, 2001; 90(6): 2508 - 2513.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Q. Chen, A. K. S. Camara, J. An, M. L. Riess, E. Novalija, and D. F. Stowe
Cardiac preconditioning with 4-h, 17{degrees}C ischemia reduces [Ca2+]i load and damage in part via KATP channel opening
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H1961 - H1969.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawabata, K.-I.
Right arrow Articles by Dhalla, N. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawabata, K.-I.
Right arrow Articles by Dhalla, N. S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online